The new version requires thrice-weekly injections instead of daily.
Copaxone delivers over 20% of the firm's revenues and 50% of its profit, so management is keen to preserve as much of the revenue stream as possible.
The company offers a $1,000 discount from the current annual cost of $60,500 as an incentive to convert to the new version.
Investors don't yet seem concerned about the issue since shares are up 23% year-to-date.
Mutual fund ownership has eased from 1054 to 967 over the past four quarters.